Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Moderna (MRNA)

Moderna appoints former Biogen CFO Michael McDonnell to its Board of Directors

Neutral Impact 3 of 5 leadership Written later

Moderna's Board appointed Michael McDonnell, former Chief Financial Officer of Biogen Inc., as a director effective July 8, 2026, and placed him on the Audit Committee. The filing describes the appointment as a board change and reports no financial results, guidance, or compensation figures beyond standard non-employee director grants.

Key points

  • Michael McDonnell was appointed to the Board effective July 8, 2026, as a Class II director serving until the 2029 annual meeting.
  • He served as Chief Financial Officer of Biogen Inc. from August 2020 through February 2025.
  • He joins the Audit Committee; David Rubenstein left the Audit Committee and joined the Nominating and Corporate Governance Committee.

The filing

CompanyModerna (MRNA)
Form8-K, current report
Filed with the SECJul 8, 2026, 7:08 AM ET
Accession number0001682852-26-000134

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:21 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 08, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.